Biocon Limited · NSE:BIOCON

Biocon — Shareholder Meeting (July 2018)

21 slides from Biocon's shareholder meeting presentation, Jul 27, 2018

  1. Slide 1: 40th Annual General Meeting: Chairperson's Speech

    40th Annual General Meeting CHAIRPERSON’S SPEECH Kiran Mazumdar-Shaw Chairperson & Managing Director July 27th, 2018 Biocon Research Centre BSE: 532523 | NSE: BIOCON | REUTERS: BION.NS | BLOOMBERG: BIOS IN | WWW.BIOCON.COM

  2. Slide 2: Welcome: 40 years of Biocon's Journey of Endurance

    Welcome 2018 marks 40 years of Biocon’s Journey of Endurance 2

  3. Slide 3: Ogivri

    Ogivri™ • 1st Biosimilar Trastuzumab approved in U.S. • 1st Biosimilar from India approved by U.S. FDA • 1st Biosimilar from Biocon-Mylan joint portfolio approved in U.S. Outcome of commitment and perseverance of thousands of Bioconites 2013-14 2017 2008-10 2011-12 CANMAB™ Launched in 2016 India App

  4. Slide 4: Semglee

    Semglee™ • 1st biosimilar from Biocon-Mylan joint portfolio approved by European Commission • Approved by TGA, Australia • Approved in Russia, South Korea 2018 2010-12 2013-15 2016-17 2009 Approved in Global PK/PD Global INSTRIDE Launched in Japan, Launched in India Study Clinical Studies UAE, Malay

  5. Slide 5: Fulphila

    Fulphila™ • 1st biosimilar Pegfilgrastim approved and launched in U.S. • 2nd biosimilar from Biocon approved in U.S. 2009-11 2015-16 2018 2016-18 Process / Analytical PK, Safety & Efficacy Filing in U.S., EU Approved & method development Study Launched in U.S. 5

  6. Slide 6: At the Right Place at the Right Time

    At the Right Place at the Right Time Biologics accounted for 11 of Top 15 drugs by value in 2017* 40+ biosimilars USD 28 approved since billion 2006 in EU USD 5 billion 2020 2018 11 biosimilars approved since Biosimilars Market: Expected Growth* 2015 in U.S. (*Source: Genetic Engineering & Biotechno

  7. Slide 7: Differentiating to Lead

    Differentiating to Lead Quality Affordability CORE VALUES Reliability Innovation We have the ‘Edge’ to produce innovative and affordable biologics at a scale that can address global needs. 7

  8. Slide 8: Making a Difference to People with Diabetes

    Making a Difference to People with Diabetes Aim to support ‘1 in 5’ insulin-dependent people with diabetes the world over 8

  9. Slide 9: Climbing the Learning Curve

    Climbing the Learning Curve Developed and launched 2 novel biologics in India Partnered with Mylan for biosimilars Partnered with Sandoz for next-gen biosimilars 9

  10. Slide 10: Path-breaking Novel Innovation

    Path-breaking Novel Innovation Supports Insulin Tregopil study in Type 1 diabetes A large investigator-led study established Nimotuzumab as 'best-in-class‘ drug to treat head & neck cancer. Results were presented at 10

  11. Slide 11: Scale Up

    Scale Up • India’s largest bio-manufacturing site in Bengaluru • Asia’s largest insulins manufacturing complex in Malaysia • Largest fermentation based bulk-drug capacities for Statins & Immunosuppressants globally 11

  12. Slide 12: Preparing for the Future

    Preparing for the Future Commissioned our first solid-oral dosage forms facility in Bengaluru Second antibodies facility coming up in Bengaluru 12

  13. Slide 13: Overcoming Regulatory Challenges

    Overcoming Regulatory Challenges Sterile DP Manufacturing Facility  Received EIR (Establishment Inspection Report) from U.S. FDA  Received EU GMP certification 13

  14. Slide 14: Financial Highlights: FY18

    Financial Highlights: FY18 Key Numbers In Rs. Million 50000 45000 43359 40787 40000 35000 30000 25000 20000 15000 10,353 11366 10000 6121 5000 3724 3804 4019 0 Net Profit* EBITDA R&D Spends Revenue FY 18 FY 17 14

  15. Slide 15: Sustainability Programs & Social Responsibility

    Sustainability Programs & Social Responsibility eLAJ Smart Clinics • 10 clinics added in Karnataka • 2.3 lakh patient visits recorded in FY18 • Jhalwar PHC declared ‘model’ PHC by Rajasthan Govt. Cancer detection program • 53,000 men and women screened for oral, breast and cervical cancers till date

  16. Slide 16: Sustainability Programs & Social Responsibility: Hebbagodi Lake Revived

    Sustainability Programs & Social Responsibility Hebbagodi Lake Revived: 34 acres Before After Cleaning debris, garbage & weeds Daily dosing of enzymes Floating wetlands & submersible aerators • Garbage, sludge & weeds removed • Eco-friendly bioremediation process deployed • Inlets cleaned, bar scree

  17. Slide 17: Social Responsibility: Skill Development

    Social Responsibility: Skill Development Focus on Developing Biotech Graduates into Industry Ready Talent • 400 students have benefitted till date from the Academy Two New Programs Introduced: • 100% placement record maintained by the Academy • Faculty Development Program (FDP) • >55% students recru

  18. Slide 18: Looking Ahead

    Looking Ahead • Biosimilars approvals to translate into accelerated revenues • Syngene poised to do well • Small Molecules, Branded Formulations to deliver positive performance • Set for sustainable long-term growth led by all businesses 18

  19. Slide 19: Thanks to Shareholders

    Thanks to Shareholders for believing in us and supporting us! 19

  20. Slide 20: Thank You

    Bs Biocon THANK YOU ©0000 — : : — a www.biocon.com

  21. Slide 21: 40th Annual General Meeting: Chairperson's Speech

    40th Annual General Meeting CHAIRPERSON’S SPEECH Kiran Mazumdar-Shaw Chairperson & Managing Director July 27th, 2018 Biocon Research Centre BSE: 532523 | NSE: BIOCON | REUTERS: BION.NS | BLOOMBERG: BIOS IN | WWW.BIOCON.COM

Biocon — Shareholder Meeting (July 2018) on 6ix